Search results for "Analogues"

showing 10 items of 68 documents

Synthesis of phosphono dipeptides, inhibitors of cathepsin C

1998

Abstract Phosphono dipeptides containing glycine, glycylglycine or L-alanine at N-termini and racemic phosphonic acid analogues of aromatic amino acids, as well as racemic alicyclic aminophosphonates, exhibit moderate inhibitory activity towards cathepsin C. This activity is probably due to the binding of the phosphonate moiety by a positively charged part of the enzyme which is complementary to the carboxylate part of the synthetic dipeptide products of the enzymatic reaction.

GlycylglycineDipeptideStereochemistryOrganic Chemistryprotease inhibitorsphosphonic acid analoguesBiochemistryPhosphonateCathepsin Csubstrate analoguesInorganic Chemistrychemistry.chemical_compoundchemistryGlycineAromatic amino acidsMoietyCarboxylate
researchProduct

3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines, nortopsentin Analogues with antiproliferative activity

2015

A new series of nortopsentin analogues, in which the imidazole ring of the natural product was replaced by thiazole and the indole unit bound to position 2 of the thiazole ring was substituted by a 7-azaindole moiety, was efficiently synthesized. Two of the new nortopsentin analogues showed good antiproliferative effect against the totality of the NCI full panel of human tumor cell lines (~60) having GI50 values ranging from low micromolar to nanomolar level. The mechanism of the antiproliferative effect of these derivatives, investigated on human hepatoma HepG2 cells, was pro-apoptotic, being associated with externalization of plasma membrane phosphatidylserine and mitochondrial dysfunctio…

IndolesHalogenationPyridines3-b]pyridinesPharmaceutical ScienceApoptosisAntiproliferative activity3-[4-(1<i>H</i>-indol-3-yl)-13-thiazol-2-yl]-1<i>H</i>-pyrrolo[23-<i>b</i>]pyridineschemistry.chemical_compoundNeoplasmsDrug DiscoveryImidazoleMoietyindolyl alkaloidsPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5Membrane Potential MitochondrialMolecular Structure3-[4-(1H-indol-3-yl)-1; 3-thiazol-2-yl]-1H-pyrrolo[2; 3-b]pyridines; Antiproliferative activity; Indolyl alkaloids; Marine alkaloids; Nortopsentin analogues; Drug Discovery3003 Pharmaceutical ScienceImidazolesPhosphatidylserineMitochondrianortopsentin analoguesIndolyl alkaloidmarine alkaloidsG2 PhaseStereochemistryNortopsentin analogueAntineoplastic AgentsMethylationResting Phase Cell CycleArticleAlkaloids3-[4-(1H-indol-3-yl)-1Cell Line TumorHumansPyrroles3-[4-(1H-indol-3-yl)-13-thiazol-2-yl]-1H-pyrrolo[23-b]pyridines3-thiazol-2-yl]-1H-pyrrolo[2ThiazoleCell ProliferationIndole testNatural productCell growthDrug Discovery3003 Pharmaceutical ScienceSettore CHIM/08 - Chimica FarmaceuticaThiazoleschemistrylcsh:Biology (General)Cell cultureDrug DesignMarine alkaloid3-[4-(1H-indol-3-yl)-13-thiazol-2-yl]-1H-pyrrolo[23-b]pyridine
researchProduct

Anion template effect and the polymerization degree

2005

Two 2D (M1 and M2) and one 1D (M3) metal‐organic frameworks (MOFs) have been prepared from pyridine functionalized tetradentate ligand tetrakis(nicotinoxymethyl)methane TNM with silver tetrafluoroborate, nickel chloride, and copper hexafluorophosphate. M1 manifests a previously unpresented mode of 4,4 threefold parallel interpenetration for 2D MOFs. Large channels (vdW diameter 9.4 Å) through eclipsed 2D layers of M2 were observed. While the open space percentage in the noninterpenetrated M2 was 38.0 %, the triple interpenetration of the sheets of M1 reduced the void to 10.8 %. With the same ligand and a similar, weakly coordinating anion as that in M1, the structure M3 was rendered one‐dim…

Inorganic chemistrychemistry.chemical_elementCrystal engineeringSelf-assemblyTransition metalsCrystal engineeringSilver tetrafluoroborateZeolite analoguesInorganic ChemistryNickelCrystallographychemistry.chemical_compoundN ligandschemistryPolymerizationTransition metalHexafluorophosphatePyridineSelf-assemblyEuropean Journal of Inorganic Chemistry
researchProduct

Nutriosomes: Prebiotic delivery systems combining phospholipids, a soluble dextrin and curcumin to counteract intestinal oxidative stress and inflamm…

2018

Nutriosomes, new phospholipid nanovesicles specifically designed for intestinal protection were developed by simultaneously loading a water-soluble dextrin (Nutriose® FM06) and a natural antioxidant (curcumin). Nutriosomes were easily fabricated in a one-step, organic solvent-free procedure. The stability and delivery performances of the vesicles were improved by adding hydroxypropyl methylcellulose. All the vesicles were small in size (mean diameter ∼168 nm), negatively charged (zeta potential ∼-38 mV, irrespective of their composition), and self-assembled predominantly in unilamellar vesicles stabilized by the presence of Nutriose®, which was located in both the inter-lamellar and inter-v…

Male0301 basic medicineBiodistributionAntioxidantCurcuminEstrès oxidatiumedicine.medical_treatmentPhospholipidBiological AvailabilityCurcumin analogues02 engineering and technologyAntioxidants03 medical and health scienceschemistry.chemical_compoundCryoprotective AgentsDrug Delivery SystemsCurcumaMicroscopy Electron TransmissionX-Ray DiffractionDextrinsScattering Small AnglemedicineZeta potentialAnimalsHumansTissue DistributionGeneral Materials ScienceRats WistarPhospholipidsInflammationchemistry.chemical_classificationVesicle021001 nanoscience & nanotechnologyRats3. Good healthBioavailabilityIntestinesOxidative StressFreeze DryingPrebiotics030104 developmental biologychemistryCurcuminBiophysicsDextrinCaco-2 Cells0210 nano-technology
researchProduct

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate &amp;gt; 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs &amp;lt; 2 cm. Methods MEN1 patients with 1 or more pNETs &amp;lt; 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genot…

2019

Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA <20 IU/mL. The primary endpoint was proportion of patients with ≥50% decline in serum HBsAg by the end of the 48-week add-on phase. Seventy patients received treatment, 11 were withdrawn at week 24 for no decrease in HBsAg, and 14 withdrew for other reasons. Response rate (per-protocol population) was 67.4% (29/43) at…

MaleHBsAgGastroenterologyPolyethylene Glycolschronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatment; Hepatology; Infectious Diseases; Virology0302 clinical medicineInterferonGenotypeHBVHepatitis B e Antigenspeginterferonchronic hepatitis b; hbeag-negative; nucleos(t)ide analogues; peginterferon; treatment; adult; antiviral agents; drug administration schedule; drug therapy combination; female; genotype; hepatitis b e antigens; hepatitis b virus; hepatitis b chronic; humans; interferon-alpha; male; middle aged; nucleosides; polyethylene glycols; recombinant proteins; treatment outcomeeducation.field_of_studytreatmentnucleos(t)ide analoguesvirus diseasesNucleosidesMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious Diseasesnucleos(t)ide analogueHBeAg030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyPeginterferon alfa-2amedicine.drugAdultHepatitis B virusmedicine.medical_specialtyGenotypeCombination therapyPopulationHBeAg-negativeInfectious DiseaseHBeAg-negative; chronic hepatitis B; nucleos(t)ide analogues; peginterferon; treatmentchronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatmentAntiviral AgentsDrug Administration Schedule03 medical and health sciencesHepatitis B ChronicInternal medicineVirologymedicineHumanschronic hepatitis BeducationHepatologybusiness.industryInterferon-alphaConfidence intervalbusiness
researchProduct

The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization

2009

The discovery and evaluation of high affinity dopamine transport inhibitors with low abuse liability is an important step toward the development of efficacious medications for cocaine addiction. We examined in mice the behavioural effects of (N-(n-butyl)-3Ά-[bis(4Ά-fluorophenyl)methoxy]-tropane) (JHW 007), a benztropine (BZT) analogue that blocks dopamine uptake, and assessed its potential to influence the actions of cocaine in clinically-relevant models of cocaine addiction. In the conditioned place preference (CPP) paradigm, JHW 007 exposure did not produce place conditioning within an ample dose range but effectively blocked the CPP induced by cocaine administration. Similarly, in the CP…

MaleLocomotor activityElevated plus mazemedia_common.quotation_subjectDopamine transportPharmacologyMotor ActivityAnxietyOpen fieldSensitizationMiceDopamine Uptake InhibitorsRewardCocaineDopaminemedicineAnimalsPharmacology (medical)Drug InteractionsMaze LearningBiological PsychiatrySensitizationmedia_commonPharmacologyBenztropineAnalysis of VarianceBehavior AnimalAddictionPlace preferenceBenztropineConditioned place preferencePsychiatry and Mental healthmedicine.anatomical_structureNeurologyConditioning OperantDopamine AntagonistsNeurology (clinical)PsychologyBenztropine analoguesmedicine.drug
researchProduct

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

2019

Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established. This study aims at identifying and comparing the main therapeutic sequences in G1−G2 NET. Methods: A retrospective observational Italian multicenter study was designed to collect data on therapeutic sequences in NET. Median progression-free survival (PFS) was compared between therapeutic sequences, as well as the number and grade of side effects and the rate of dose reduction/treatment discontinuation. Results: Among 1182 patients with neuroendocrine neoplasia included in the ELIOS database, 131 G1–G2 ga…

MaleOncologymedicine.medical_specialtyHigh-dose somatostatin analogs; neuroendocrine tumors; PRRT; sequence of treatments; somatostatin analogues; targeted therapyLung NeoplasmsDatabases FactualSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic AgentsHigh-dose somatostatin analogNeuroendocrine tumorsOctreotideSomatostatin analogueTargeted therapySettore MED/13 - EndocrinologiaTargeted therapyEndocrinologyNeuroendocrine tumorStomach NeoplasmsInternal medicineDiabetes mellitusIntestinal NeoplasmsSequence of treatmentmedicineHumansEverolimusRetrospective StudiesChemotherapyEverolimusbusiness.industryDisease ManagementMiddle Agedmedicine.diseaseDiscontinuationPancreatic NeoplasmsNeuroendocrine TumorsRadionuclide therapyFemaleObservational studyPRRTSomatostatinbusinessmedicine.drug
researchProduct

Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues

2008

Predictive quantitative structure-activity relationship (QSAR) models of anabolic and androgenic activities for the testosterone and dihydrotestosterone steroid analogues were obtained by means of multiple linear regression using quantum and physicochemical molecular descriptors (MD) as well as a genetic algorithm for the selection of the best subset of variables. Quantitative models found for describing the anabolic (androgenic) activity are significant from a statistical point of view: R2 of 0.84 (0.72 and 0.70). A leave-one-out cross-validation procedure revealed that the regression models had a fairly good predictability [q2 of 0.80 (0.60 and 0.59)]. In addition, other QSAR models were …

MaleQuantitative structure–activity relationshipAnabolismStereochemistrymedicine.medical_treatmentClinical BiochemistryAnabolic and androgenic activitiesQSAR modelQuantitative Structure-Activity RelationshipPharmaceutical ScienceBiochemistrySteroidAnabolic AgentsMolecular descriptorDrug DiscoveryLinear regressionmedicineCluster AnalysisHumansComputer SimulationTestosteroneMolecular BiologyChemistryOrganic ChemistryDihydrotestosteroneModels ChemicalGenetic algorithmDihydrotestosteroneAndrogensQuantum and physicochemical molecular descriptorMolecular MedicineTestosterone and dihydrotestosterone steroid analoguesAlgorithmsAnabolic steroidApplicability domainmedicine.drugBioorganic and Medicinal Chemistry 16: 6448-6459 (2008)
researchProduct

Thymidylate synthases from Hymenolepis diminuta and regenerating rat liver: purification, properties, and inhibition by substrate and cofactor analog…

1995

Comparative studies of thymidylate synthases, isolated from the tapeworm, Hymenolepis diminuta, and regenerating liver of its host, rat, aimed at a possibility of specific inhibition of the helminthic enzyme, are presented. While similar in structure (dimers with monomer molecular masses of 33.7 kDa and 34.9 kDa, respectively) and parameters describing interactions with substrates and products, the tapeworm and rat enzymes differed in the dependences of reaction velocity on temperature (Arrhenius plots biphasic and linear, respectively). The tapeworm, compared with the host, enzyme was less sensitive to the competitive slow-binding inhibition by 5-fluoro-dUMP and its 2-thio congener, but eq…

MaleStereochemistryBiophysicsBiochemistryThymidylate synthaseCofactorchemistry.chemical_compoundmethylenetetrahydrofolate analoguesNon-competitive inhibitionStructural BiologyValineFluorodeoxyuridylateAnimalsRats WistardUMPenzyme inhibitionMolecular BiologyTetrahydrofolatesHelminthic enzymechemistry.chemical_classificationAlaninebiologyTemperatureThymidylate SynthaseHymenolepis diminutabiology.organism_classificationLiver RegenerationRatsMolecular WeightKineticsEnzymechemistryBiochemistryLiverbiology.proteinNorvalineanalogues(H. diminuta)HymenolepisBiochimica et biophysica acta
researchProduct